Bevacizumab offers no benefit for newly diagnosed glioblastoma, study finds
The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research ...
Jun 2, 2013
0
0